Jazz Pharmaceuticals plc (JAZZ)
NASDAQ: JAZZ · IEX Real-Time Price · USD
110.43
+3.00 (2.79%)
Apr 26, 2024, 3:38 PM EDT - Market open
Jazz Pharmaceuticals Stock Forecast
Stock Price Forecast
The 14 analysts with 12-month price forecasts for JAZZ stock have an average target of 193.43, with a low estimate of 131 and a high estimate of 230. The average target predicts an increase of 75.16% from the current stock price of 110.43.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for JAZZ stock from 15 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Nov '23 | Dec '23 | Jan '24 | Feb '24 | Mar '24 | Apr '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 5 | 5 | 5 | 5 | 5 |
| Buy | 2 | 2 | 4 | 6 | 7 | 7 |
| Hold | 3 | 3 | 3 | 3 | 3 | 3 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 9 | 10 | 12 | 14 | 15 | 15 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates $180 | Buy | Reiterates | $180 | +63.00% | Apr 10, 2024 |
| JP Morgan | JP Morgan | Buy Maintains $170 → $190 | Buy | Maintains | $170 → $190 | +72.05% | Mar 22, 2024 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates $180 | Buy | Reiterates | $180 | +63.00% | Mar 22, 2024 |
| Truist Securities | Truist Securities | Strong Buy Reiterates $200 | Strong Buy | Reiterates | $200 | +81.11% | Mar 20, 2024 |
| Piper Sandler | Piper Sandler | Buy Reiterates $171 → $188 | Buy | Reiterates | $171 → $188 | +70.24% | Mar 20, 2024 |
Financial Forecast
Revenue This Year
4.19B
from 3.83B
Increased by 9.20%
Revenue Next Year
4.48B
from 4.19B
Increased by 7.09%
EPS This Year
19.34
from 6.10
Increased by 217.12%
EPS Next Year
21.46
from 19.34
Increased by 10.95%
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 4.5B | 4.9B | 5.3B | 5.4B | 5.4B |
| Avg | 4.2B | 4.5B | 4.7B | 4.8B | 4.8B |
| Low | 3.9B | 4.1B | 4.1B | 3.8B | 4.0B |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 16.9% | 16.3% | 18.9% | 16.5% | 13.5% |
| Avg | 9.2% | 7.1% | 4.2% | 2.2% | -0.0% |
| Low | 2.3% | -3.2% | -8.5% | -18.3% | -16.3% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 20.74 | 26.93 | 26.99 | 30.82 | 35.07 |
| Avg | 19.34 | 21.46 | 22.21 | 22.70 | 22.04 |
| Low | 18.11 | 16.91 | 15.89 | 14.68 | 15.20 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 240.0% | 39.2% | 25.7% | 38.7% | 54.5% |
| Avg | 217.1% | 11.0% | 3.5% | 2.2% | -2.9% |
| Low | 196.9% | -12.6% | -26.0% | -33.9% | -33.0% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.